The single mouse trial (SMT) format for in vivo patient-derived xenograft (PDX) studies addresses the need for compound testing in larger, more diverse tumor populations. This format employs a single mouse per PDX model and treatment arm, thereby enabling a cost-effective investigation of in vivo efficacy in large panels of PDX models. The SMT format reliably identifies compounds that are strongly active (or inactive) across a panel of tumor models, and can be used to investigate the most promising compounds, new indications or optimal drug combinations.

Presenter

  • Nina Zanella, DVM, PhD, Oncotest, a Charles River Company